Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population

Georgios Angelidakis; Fareed Khawaja; Victor E. Mulanovich; Natalie Dailey-Garnes; Ella Ariza-Heredia; Roy F. Chemaly

doi:10.1016/j.micinf.2021.104895

Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population

Georgios Angelidakis, Fareed Khawaja, Victor E. Mulanovich, Natalie Dailey-Garnes, Ella Ariza-Heredia, Roy F. Chemaly

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.

Original language	English (US)
Article number	104895
Journal	Microbes and Infection
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/j.micinf.2021.104895
State	Published - Apr 1 2022

Keywords

Baloxavir
Combination therapy
HCT
Influenza
Oseltamivir

ASJC Scopus subject areas

Microbiology
Immunology
Infectious Diseases

Access to Document

10.1016/j.micinf.2021.104895

Cite this

Angelidakis, G., Khawaja, F., Mulanovich, V. E., Dailey-Garnes, N., Ariza-Heredia, E., & Chemaly, R. F. (2022). Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. Microbes and Infection, 24(3), Article 104895. https://doi.org/10.1016/j.micinf.2021.104895

Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. / Angelidakis, Georgios ; Khawaja, Fareed ; Mulanovich, Victor E. et al.
In: Microbes and Infection, Vol. 24, No. 3, 104895, 01.04.2022.

Research output: Contribution to journal › Article › peer-review

Angelidakis, G , Khawaja, F , Mulanovich, VE , Dailey-Garnes, N , Ariza-Heredia, E & Chemaly, RF 2022, 'Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population', Microbes and Infection, vol. 24, no. 3, 104895. https://doi.org/10.1016/j.micinf.2021.104895

@article{6d042204ac2249bbb7558804251f5bba,

title = "Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population",

abstract = "Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.",

keywords = "Baloxavir, Combination therapy, HCT, Influenza, Oseltamivir",

author = "Georgios Angelidakis and Fareed Khawaja and Mulanovich, {Victor E.} and Natalie Dailey-Garnes and Ella Ariza-Heredia and Chemaly, {Roy F.}",

note = "Publisher Copyright: {\textcopyright} 2021 Institut Pasteur",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.micinf.2021.104895",

language = "English (US)",

volume = "24",

journal = "Microbes and Infection",

issn = "1286-4579",

publisher = "Elsevier Masson SAS",

number = "3",

}

TY - JOUR

T1 - Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients

T2 - a novel treatment strategy for a high-risk population

AU - Angelidakis, Georgios

AU - Khawaja, Fareed

AU - Mulanovich, Victor E.

AU - Dailey-Garnes, Natalie

AU - Ariza-Heredia, Ella

AU - Chemaly, Roy F.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.

AB - Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.

KW - Baloxavir

KW - Combination therapy

KW - HCT

KW - Influenza

KW - Oseltamivir

UR - http://www.scopus.com/inward/record.url?scp=85129220848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129220848&partnerID=8YFLogxK

U2 - 10.1016/j.micinf.2021.104895

DO - 10.1016/j.micinf.2021.104895

M3 - Article

C2 - 34756990

AN - SCOPUS:85129220848

SN - 1286-4579

VL - 24

JO - Microbes and Infection

JF - Microbes and Infection

IS - 3

M1 - 104895

ER -

Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this